Uchiyama-Tanaka Yoko, Shimabukuro Fumi, Okumura Eri, Fujishima Masaki
Yoko Clinic Kitakyushu, Fukuoka Japan.
Yui Clinic Noborikawa Okinawa Japan.
Food Sci Nutr. 2023 Oct 16;12(1):292-297. doi: 10.1002/fsn3.3759. eCollection 2024 Jan.
Pregnancy dramatically changes maternal metabolism and the microbiome. Low-grade inflammation can cause maternal complications and fetal abnormalities. The objective of this open-label, randomized, controlled study was to evaluate the efficacy and safety of orally administered , a green alga that is commercially available as a dietary supplement with rich nutrients and dietary fiber for pregnant women with low-grade inflammation. Patients with C-reactive protein levels >0.05 mg/dL (16 weeks gestation, = 22) were enrolled and randomly allocated to the group ( = 10) or control group ( = 12). We conducted blood biochemical tests at 25, 30, and 35 weeks gestation and evaluated the evacuation status (symptoms depending on the Rome IV C2 criteria and laxative usage), side effects, and complications throughout the investigation. We also monitored the status of the offspring. The group ( = 0) showed a significantly lower rate of constipation than the control group ( = 8). This study demonstrated the beneficial effects and safety of supplementation in pregnant women, which prevented constipation and unnecessary laxative administration.
怀孕会极大地改变母体代谢和微生物群。低度炎症会导致母体并发症和胎儿异常。这项开放标签、随机、对照研究的目的是评估口服 (一种绿藻,作为富含营养和膳食纤维的膳食补充剂在市场上出售,用于患有低度炎症的孕妇)的疗效和安全性。C反应蛋白水平>0.05 mg/dL(妊娠16周,n = 22)的患者被纳入研究,并随机分配到 组(n = 10)或对照组(n = 12)。我们在妊娠25、30和35周时进行了血液生化检测,并在整个研究过程中评估了排便情况(根据罗马IV C2标准的症状和泻药使用情况)、副作用和并发症。我们还监测了后代的状况。 组(n = 0)的便秘发生率明显低于对照组(n = 8)。这项研究证明了在孕妇中补充 的有益效果和安全性,它预防了便秘和不必要的泻药使用。